PALM BEACH GARDENS, Fla., Nov. 27 /PRNewswire/ -- MediSys Corporation CEO Joshua Konigsberg announced that October’s UroToday(R) reported that Erectile Dysfunction (ED) and Coronary Artery Disease (CAD) frequently coexist. The abstract quoted is based on highly credible industry sources that have MediSys thrilled about the future of its business.
The American Urology Association abstract quoted is based on research performed by Italian researchers. In the study, the number of diseased coronary arteries, age, and diabetes were statistically significant and independent predictors of ED. Patients with ED had a four-fold increase in the risk of multi-vessel Coronary Artery Disease. The researchers concluded that ED is frequently found in patients with Acute Coronary Syndrome, and ED presence is a useful test to predict extension of Coronary Artery Disease in Acute Coronary Syndrome.
While MediSys has been demonstrating that ED is a condition linked to many underlying diseases since commencing development of the MaxLife Centers for Men(TM) in late 2002, only recently has the mainstream medical community started recognizing the relationship between such diseases as coronary artery disease and ED.
CEO Konigsberg said, “What is important about these additional findings is that it will increase our credibility to patients in our licensed clinics for the right reasons; to uncover the underlying disease and not just for sexual restoration. All of our MaxLife Center for Men(TM) licensed clinics are qualified to identify these diseases (and others) earlier in the disease process, and thus they can improve the quality of patient care.”
Dr. Ralph Benson, MediSys’ Medical Director, a past Chairman of Urology at the Mayo Clinic in Jacksonville, FL said, “This is important news and proves MediSys Corporation is ahead of the curve and has been -- and is -- on the right track. The Medical Community seems to be catching up.”
About MediSys:
MediSys Corporation provides medical diagnostic solutions to physicians in the internal medicine, family medicine, and general practice markets. The company’s innovative clinical programs are easily integrated into the physicians practice, are cost-effective, and enhance patient care. These programs or “systems” enable doctors to provide superior medical diagnostics & treatment while significantly improving their revenues and profits.
Disclaimer Regarding Forward-Looking Statements:
This announcement may contain certain forward-looking statements that are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from the assumptions currently anticipated. Forward-looking statements speak only as of the date the statement was made. The Company assumes no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. If the Company does update any forward-looking statement, no inference should be drawn that the Company will make additional updates with respect to that statement or any other forward-looking statements.
Contact: Brian Gibson, 800 Village Square Crossing, Suite 201, Palm Beach Gardens, FL 33410 561-622-5889 -- investor-relations@medisyscorp.comwww.medisyscorp.com
MediSys Corporation
CONTACT: Brian Gibson of MediSys Corporation, +1-561-622-5889,investor-relations@medisyscorp.com
Web site: http://www.medisyscorp.com/